Assessing RLI (RLI) Valuation As Nepsis Ups Its Stake And Analyst Coverage Expands

Institutional buying and fresh coverage put RLI in focus

Nepsis Inc.’s latest SEC filing shows a sizeable top-up to its RLI (RLI) position, now one of the fund’s largest holdings. The move arrives just as new analyst coverage and earnings expectations draw fresh attention to the insurer.

See our latest analysis for RLI.

At a share price of US$59.35, RLI has had a 1 month share price return of a 10.14% decline and a year to date share price return of a 5.01% decline, while the 1 year total shareholder return of a 20.36% decline contrasts with a 5 year total shareholder return of 41.40%. This suggests that shorter term momentum has faded even as longer term holders are still ahead.

If Nepsis increasing its stake has you thinking about other insurance names, it could be a good moment to scan the market for stable growth stocks screener (None results) as a comparison set.

With RLI trading at US$59.35, a value score of 1 and modest revenue growth alongside weaker net income, the real question is whether the recent pullback leaves mispricing on the table or if the market is already factoring in future growth.

Most Popular Narrative: 9% Undervalued

The most followed valuation narrative puts RLI’s fair value at US$65.25, above the last close of US$59.35, framing the current price as a potential discount.

The analysts have a consensus price target of $74.333 for RLI based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $87.0, and the most bearish reporting a price target of just $59.0.

Read the complete narrative.

Curious what justifies a higher fair value when earnings are expected to contract and revenue growth sits near flat? The narrative leans heavily on margin assumptions and the future P/E investors might be willing to pay. Want to see how those moving parts interact over time and what discount rate ties it all together?

Result: Fair Value of $65.25 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that underpriced story can break if softer property markets squeeze underwriting margins or if higher technology and acquisition costs keep expense ratios elevated for longer.

Find out about the key risks to this RLI narrative.

Another angle on valuation

Analysts and the fair value narrative see RLI trading at a discount, but its current P/E of 15.4x tells a different story. That multiple sits above the US Insurance industry at 12.8x, its peer average at 11.2x, and the fair ratio of 10.2x that our work suggests the market could move toward. For you, that raises a simple question: is the recent share price weakness enough to offset paying a richer multiple than both the sector and RLI’s own fair ratio?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own RLI Narrative

If parts of this story do not sit right with you or you would rather trust your own work, you can stress test the numbers yourself and build a version that fits your view in just a few minutes, starting with Do it your way.

A great starting point for your RLI research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If RLI has sparked your interest, it is worth lining it up against other stock ideas so you can see where the most compelling stories might sit.

• Spot potential value setups by scanning these 863 undervalued stocks based on cash flows that could offer prices below what their fundamentals suggest.
• Tap into the potential of machine learning and automation with these 24 AI penny stocks that focus on real business use cases, not just buzzwords.
• Position yourself early in a fast evolving space by sizing up these 80 cryptocurrency and blockchain stocks tied to blockchain and digital asset themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com